{"slideshow_credits": null, "snippet": "Elan, an Irish drug maker that is the target of a hostile takeover, agreed to pay $1 billion for a share of royalties on new drugs from Theravance of the United States.", "abstract": "Elan, an Irish drug maker that is the target of a hostile takeover, agreed to pay $1 billion for a share of royalties on new drugs from Theravance of the United States.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Julia", "role": "reported", "lastname": "WERDIGIER", "rank": 1, "organization": ""}], "original": "By JULIA WERDIGIER"}, "web_url": "http://dealbook.nytimes.com/2013/05/13/elan-in-deal-on-drug-royalties/", "lead_paragraph": null, "headline": {"main": "Elan in Deal on Drug Royalties", "kicker": "DealBook"}, "_id": "5190da5d40e9ec457e2a0da7", "word_count": "364", "multimedia": [], "pub_date": "2013-05-13T06:36:34Z", "source": "The New York Times", "news_desk": null, "keywords": [], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}